AngioDynamics, Inc. (NASDAQ:ANGO) Director Kevin J. Gould sold 13,650 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total value of $292,792.50. Following the sale, the director now owns 61,774 shares of the company’s stock, valued at approximately $1,325,052.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ ANGO opened at $21.19 on Friday. The company has a market capitalization of $788.61 million, a P/E ratio of 25.53 and a beta of 0.69. AngioDynamics, Inc. has a 52 week low of $18.11 and a 52 week high of $25.48. The firm’s 50 day moving average price is $19.94. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.26 by ($0.01). The firm had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.20 EPS. On average, equities analysts expect that AngioDynamics, Inc. will post 0.27 EPS for the current year.
ANGO has been the subject of several recent research reports. ValuEngine downgraded Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. TheStreet downgraded Upland Software from a “b-” rating to a “c+” rating in a report on Wednesday, July 10th. Finally, Zacks Investment Research upgraded Investar from a “hold” rating to a “buy” rating and set a $27.00 price objective for the company in a report on Tuesday, June 4th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $21.50.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.